BE886259A - Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique - Google Patents

Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique Download PDF

Info

Publication number: BE886259A
Authority: BE; Belgium
Prior art keywords: emi; carbon atoms; group; carbon; alkyl
Prior art date: 1979-11-23

Application number

BE1/10043A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-11-23

Filing date

1980-11-20

Publication date

1981-05-20

1980-11-20 Application filed by Sandoz Sa filed Critical Sandoz Sa

1981-05-20 Publication of BE886259A publication Critical patent/BE886259A/fr

Links

YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title claims description 4
239000003814 drug Substances 0.000 title claims description 4
229940079593 drug Drugs 0.000 title claims 2
230000007812 deficiency Effects 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
206010058842 Cerebrovascular insufficiency Diseases 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
208000026106 cerebrovascular disease Diseases 0.000 claims description 7
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000000812 cholinergic antagonist Substances 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000003884 phenylalkyl group Chemical group 0.000 claims description 4
230000002048 spasmolytic effect Effects 0.000 claims description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000003302 alkenyloxy group Chemical group 0.000 claims description 2
125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 2
125000005133 alkynyloxy group Chemical group 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
125000004414 alkyl thio group Chemical group 0.000 claims 1
125000000304 alkynyl group Chemical group 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 20
239000002775 capsule Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000000694 effects Effects 0.000 description 3
-1 mann & tol Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940032147 starch Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
230000003727 cerebral blood flow Effects 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004040 coloring Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000036313 post-ischemic recovery Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BE1/10043A 1979-11-23 1980-11-20 Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique BE886259A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7940624		1979-11-23

Publications (1)

Publication Number	Publication Date
BE886259A true BE886259A (fr)	1981-05-20

Family

ID=10509391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE1/10043A BE886259A (fr)	1979-11-23	1980-11-20	Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique

Country Status (4)

Country	Link
JP (1)	JPS5687522A (it)
AU (1)	AU545685B2 (it)
BE (1)	BE886259A (it)
IT (1)	IT1128630B (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986002836A1 (en) *	1984-11-12	1986-05-22	Sandoz Ag	New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5545075B2 (it) *	1973-11-29	1980-11-15
DE2508181A1 (de) *	1975-02-26	1976-09-09	Bayer Ag	1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CA1105477A (en) *	1976-03-22	1981-07-21	Edwin J. Quinn	Structurally regulated polyphosphazene copolymers
FI64938C (fi) *	1977-06-20	1984-02-10	Sandoz Ag	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara bensoxa- och bensotiadiazolyl-1,4-dihydropyridinderivat
JPS5844066B2 (ja) *	1978-06-16	1983-09-30	釜屋化学工業株式会社	輸液瓶の製造方法

1980
- 1980-11-20 BE BE1/10043A patent/BE886259A/fr not_active IP Right Cessation
- 1980-11-21 JP JP16344780A patent/JPS5687522A/ja active Granted
- 1980-11-21 AU AU64603/80A patent/AU545685B2/en not_active Expired
- 1980-11-21 IT IT50217/80A patent/IT1128630B/it active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986002836A1 (en) *	1984-11-12	1986-05-22	Sandoz Ag	New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins

Also Published As

Publication number	Publication date
AU545685B2 (en)	1985-07-25
JPH0138088B2 (it)	1989-08-11
IT1128630B (it)	1986-05-28
IT8050217A0 (it)	1980-11-21
JPS5687522A (en)	1981-07-16
AU6460380A (en)	1981-05-28

Legal Events

Date

Code

Title

Description

2000-01-01

RE20

Patent expired

Owner name: NOVARTIS A.G.

Effective date: 20001120

Publication	Publication Date	Title
EP0017195B1 (en)	1984-07-04	Derivatives of 2,5-disubstituted-cyclohexane-1,3-diones, process for preparation thereof and pharmaceutical composition containing them
FR2774591A1 (fr)	1999-08-13	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR2663633A1 (fr)	1991-12-27	Nouvelles chalcones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2501506A1 (fr)	1982-09-17	Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
BE886259A (fr)	1981-05-20	Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique
MC1332A1 (fr)	1981-04-21	Nouveaux derives de quinazoline et preparations pharmaceutiques
JPS62138492A (ja)	1987-06-22	新規化合物、その製法及びそれを含む医薬組成物
FR2489318A1 (fr)	1982-03-05	Sel d'acide((1-benzyl-1h-indazol-3-yl)oxy)acetique avec la lysine
LU83928A1 (fr)	1983-06-07	Acides amino-2 halogenobenzoyl-3 methyphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques
AU639722B2 (en)	1993-08-05	Use of arylalkylamides in the treatment of neurodegenerative diseases
FR2544614A1 (fr)	1984-10-26	Nouvelle association medicamenteuse pour le traitement de l'hypertension
FR2490092A1 (fr)	1982-03-19	Nouvelles compositions pharmaceutiques a base d'un derive de la 1,4-dihydropyridine
MXPA02011862A (es)	2003-04-10	5-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
JP2001523659A (ja)	2001-11-27	細胞外グルタミン酸濃度を低下させるための４位置換２−ピロリジノン誘導体
JP2838282B2 (ja)	1998-12-16	血管攣縮治療剤
FR2639227A1 (fr)	1990-05-25	Utilisation de derives du chromane pour le traitement des etats depressifs
JPH02193922A (ja)	1990-07-31	細胞保護用組成物
LU85348A1 (fr)	1985-03-21	Nouveaux derives d'acylaminophenols,leur preparation et leur utilisation comme medicaments
EP0179076B1 (fr)	1988-10-26	Derives sulfures de l'hydantoine et compositions pharmaceutiques les contenant
FR2723372A1 (fr)	1996-02-09	Nouveaux derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent
BE1000783A3 (fr)	1989-04-04	Derives du 1,3-dioxolanne et du 1,3-dioxanne et leur utilisation comme medicaments.
BE881717A (fr)	1980-08-14	Medicament a base d'un compose heterocyclique bicyclique condense
JPH05194220A (ja)	1993-08-03	高血圧症治療用の組成物及び方法
FR2585573A1 (fr)	1987-02-06	Medicament pour prevenir l'abus d'alcool
FR2834640A1 (fr)	2003-07-18	Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete

BE886259A - Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=10509391

Family Applications (1)

Country Status (4)

Cited By (1)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents

Legal Events